In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
News|Articles|October 4, 2023
Advarra Launches New Technology to Align Patients, Sites, and Sponsors in Clinical Trials
Advertisement
Advarra has announced new technology functionality to its solution, Longboat, an established platform used in more than 70 countries and by nearly 20,000 sites. It now features an online patient portal with a set of engagement tools including a document exchange that enables transparent collaboration between patients, sites, and sponsors or clinical research organizations (CROs) without adding technology burden.
Because the patient portal module is part of the same platform the site uses for essential document collection, training/learning management, study conduct enablement tools, and safety letter viewing and acknowledgement, sites are able to provide a more connected experience for their patients with this workflow.
"We've been listening to sites who are drowning in administrative tasks, repeatedly entering the same information, having to log into multiple systems or feeling out of the loop with direct communication between the sponsor and patient," said Elisa Cascade, chief product officer at Advarra in a press release. "A connected system with site, sponsor, CRO, and patient access provides visibility to all while preserving the site-patient relationship. This transparent collaboration in real time is a win for everyone involved in the study."
Reference
Advarra Launches Next-Generation Technology to Align Patients, Sites, and Sponsors in Clinical Trials. (2023, October 4). Cision PR Newswire.
Advertisement
Related to this article
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
Where AI Governance in Clinical Development Falls Short
4
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
5